TCT-709 Oral Anticoagulation Versus Left Atrial Appendage Closure in Active Cancer Patients With Atrial Fibrillation: A Comparative Analysis of Safety and Efficacy
Document Type
Abstract
Publication Date
10-28-2025
Abstract
Background: Atrial fibrillation (AFib) management in patients with active malignancy is challenging due to heightened thromboembolic and bleeding risks. Oral anticoagulation (OAC) remains standard, but left atrial appendage closure (LAAC) may provide a non-pharmacologic alternative. we wanted to compare clinical safety and efficacy outcomes of OAC versus LAAC in patients with active cancer and non-valvular AFib. Methods: A retrospective analysis of pooled data from multicenter observational cohorts including 1,432 patients (OAC: n = 932; LAAC: n = 500) with active cancer and AFib. Outcomes included stroke, major bleeding, and all-cause mortality at 12 months. Results: Stroke occurred in 2.3% of LAAC vs. 3.8% of OAC patients (p = 0.12). Major bleeding occurred in 4.4% of LAAC vs. 11.1% of OAC patients (p < 0.001). All-cause mortality was lower in LAAC patients (14.6% vs. 20.3%, p = 0.01). Conclusion: In cancer patients with AFib, LAAC demonstrated similar stroke prevention but significantly lower bleeding and mortality rates compared to OAC, suggesting it may be a safer long-term option for select high-risk patients. Categories: STRUCTURAL: Left Atrial Appendage Exclusion
Publication Title
Journal of the American College of Cardiology
Volume
86
Issue
17 Supplement
First Page
B310
Last Page
B310
Recommended Citation
Cilingiroglu, M., Inanc, I., Marmagkiollis, K., & Iliescu, C. (2025). TCT-709 Oral Anticoagulation Versus Left Atrial Appendage Closure in Active Cancer Patients With Atrial Fibrillation: A Comparative Analysis of Safety and Efficacy. Journal of the American College of Cardiology, 86 (17 Supplement), B310-B310. https://doi.org/https://doi.org/10.1016/j.jacc.2025.09.868
Comments
Transcatheter Cardiovascular Therapeutics held 2025-10-25 to 2025-10-28 in San Francisco, CA